[go: up one dir, main page]

TNSN00064A1 - Procedes et produits intermediaires pour la preparation de composes anti-cancereux - Google Patents

Procedes et produits intermediaires pour la preparation de composes anti-cancereux

Info

Publication number
TNSN00064A1
TNSN00064A1 TNTNSN00064A TNSN00064A TNSN00064A1 TN SN00064 A1 TNSN00064 A1 TN SN00064A1 TN TNSN00064 A TNTNSN00064 A TN TNSN00064A TN SN00064 A TNSN00064 A TN SN00064A TN SN00064 A1 TNSN00064 A1 TN SN00064A1
Authority
TN
Tunisia
Prior art keywords
products
preparation
compounds
cancer compounds
intermediate processes
Prior art date
Application number
TNTNSN00064A
Other languages
English (en)
Inventor
Norris Timothy
Shelton Lehner Richard
Paul Santafianos Dinos
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00064A1 publication Critical patent/TNSN00064A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES PROCEDES ET DES PRODUITS INTERMEDIAIRES POUR LA PREPARATION DE COMPOSES DE FORMULE I : ET DE LEURS PRODUITS DE SOLVATATION ET SELS ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE, AINSI QUE DES COMPOSES DE STRUCTURE APPARENTEE, OU R1, R2 ET R15 SONT DES RADICAUX ORGANIQUES, R15 POUVANT AUSSI ETRE L'HYDROGENE. CES COMPOSES SONT UTILES DANS LE TRAITEMENT DE MAMMIFERES ATTEINTS DE TROUBLES HYPERPROLIFERATIFS, TELS QUE DES CANCERS
TNTNSN00064A 1999-03-31 2000-03-29 Procedes et produits intermediaires pour la preparation de composes anti-cancereux TNSN00064A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
TNSN00064A1 true TNSN00064A1 (fr) 2005-11-10

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00064A TNSN00064A1 (fr) 1999-03-31 2000-03-29 Procedes et produits intermediaires pour la preparation de composes anti-cancereux

Country Status (49)

Country Link
US (1) US6476040B1 (fr)
EP (1) EP1044969B1 (fr)
JP (2) JP3420549B2 (fr)
KR (2) KR100430210B1 (fr)
CN (2) CN100351242C (fr)
AP (2) AP1265A (fr)
AR (1) AR018705A1 (fr)
AT (1) ATE348098T1 (fr)
AU (2) AU781402B2 (fr)
BG (1) BG65194B1 (fr)
BR (1) BRPI0001486B8 (fr)
CA (2) CA2427221C (fr)
CO (1) CO5160273A1 (fr)
CR (1) CR6165A (fr)
CZ (1) CZ299426B6 (fr)
DE (1) DE60032275T2 (fr)
DK (1) DK1044969T3 (fr)
DZ (1) DZ3030A1 (fr)
EA (3) EA004654B1 (fr)
EE (1) EE04589B1 (fr)
EG (1) EG22506A (fr)
ES (1) ES2278578T3 (fr)
GE (1) GEP20022653B (fr)
GT (1) GT200000037A (fr)
HR (1) HRP20000182B1 (fr)
HU (1) HU227698B1 (fr)
ID (1) ID25427A (fr)
IL (2) IL168036A (fr)
IS (1) IS2468B (fr)
MA (1) MA25087A1 (fr)
MY (1) MY136270A (fr)
NO (2) NO321952B1 (fr)
NZ (2) NZ512818A (fr)
OA (1) OA11335A (fr)
PA (1) PA8491901A1 (fr)
PE (1) PE20001599A1 (fr)
PL (1) PL339330A1 (fr)
PT (1) PT1044969E (fr)
RS (1) RS49836B (fr)
SG (2) SG121687A1 (fr)
SK (1) SK287339B6 (fr)
SV (1) SV2002000047A (fr)
TN (1) TNSN00064A1 (fr)
TR (1) TR200000837A2 (fr)
TW (1) TW553939B (fr)
UA (2) UA70928C2 (fr)
UY (1) UY26086A1 (fr)
YU (1) YU13200A (fr)
ZA (1) ZA200001586B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
EP1415987B1 (fr) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Composes heteroaromatiques azotes pour le traitement des maladies de cancer
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
ES2305844T3 (es) 2003-09-16 2008-11-01 Astrazeneca Ab Derivados de quinazolina como inhibidores de tirosina cinasa.
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
WO2005044788A1 (fr) 2003-11-11 2005-05-19 Eisai Co., Ltd. Derive d'uree et son procede de production
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
CA2592900A1 (fr) 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes et utilisation therapeutique associee
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
CN101163468A (zh) 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
EP1925941B1 (fr) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Procédé de prédiction de l'efficacité d'un inhibiteur de vascularisation
EP2281901B1 (fr) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
CA2627598C (fr) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Utilisation d'une combinaison de substance anti-angiogenique et d'inhibiteur de kinase c-kit
WO2007061127A1 (fr) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Agent antitumeur pour myelomes multiples
WO2007136103A1 (fr) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
EP2044939A1 (fr) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
EP2116246A1 (fr) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition destinée au traitement du cancer pancréatique
EP2119707B1 (fr) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
WO2008102369A1 (fr) * 2007-02-21 2008-08-28 Natco Pharma Limited Nouveaux polymorphes destinés de chlorhydrate d'erlotinibe et procédé de fabrication
KR20140069232A (ko) 2007-04-04 2014-06-09 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
MX2010002081A (es) * 2007-08-23 2010-06-01 Plus Chemicals Sa Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
CA2704000C (fr) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combinaison d'une substance antiangiogenique et d'un complexe de platine antitumoral
KR101506062B1 (ko) * 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 저해 물질과 탁산의 병용
US20090269354A1 (en) * 2008-03-28 2009-10-29 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
EP2307386A1 (fr) * 2008-07-07 2011-04-13 Plus Chemicals S.A. Formes cristallines de l'erlotinib base et du chlorhydrate d'erlotinib
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (fr) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Procédés de préparation du chlorhydrate d'erlotinib
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EP2411373B1 (fr) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Procede de preparation d'erlotinib ou de ses sels pharmaceutiquement acceptables
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
ES2564797T3 (es) 2009-08-19 2016-03-29 Eisai R&D Management Co., Ltd. Composición farmacéutica con contenido en un derivado de quinolina
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (fr) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
NZ606042A (en) 2010-07-23 2015-05-29 Generics Uk Ltd Process for the preparation of erlotinib and salts thereof
IT1402029B1 (it) * 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (fr) 2012-09-04 2014-03-13 Shilpa Medicare Limited Procédé de préparation de la forme cristalline de chlorhydrate d'erlotinib
WO2014098176A1 (fr) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Forme amorphe de dérivé de quinoline et son procédé de production
WO2014118737A1 (fr) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Sels d'erlotinib
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
CA2908441A1 (fr) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Procede de preparation d'erlotinib
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
ES2887426T3 (es) 2015-08-20 2021-12-22 Eisai R&D Man Co Ltd Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
ES2332984T3 (es) * 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
MEP42008A (en) 1998-04-29 2011-02-10 Osi Farmaceuticals Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
GEP20022653B (en) 2002-03-25
NO324745B1 (no) 2007-12-03
DZ3030A1 (fr) 2004-03-27
AP1655A (en) 2006-09-01
NO20001648L (no) 2000-10-02
JP2003176274A (ja) 2003-06-24
IS2468B (is) 2008-12-15
CZ20001155A3 (cs) 2001-03-14
EA200000274A3 (ru) 2003-02-27
NZ512818A (en) 2003-01-31
DE60032275T2 (de) 2007-07-12
CN1699350A (zh) 2005-11-23
BR0001486A (pt) 2001-05-02
CN1215061C (zh) 2005-08-17
GT200000037A (es) 2001-09-21
EP1044969B1 (fr) 2006-12-13
KR20020084903A (ko) 2002-11-13
ZA200001586B (en) 2001-10-01
TR200000837A2 (tr) 2000-11-21
SV2002000047A (es) 2002-01-23
MA25087A1 (fr) 2000-10-01
AU781402B2 (en) 2005-05-19
CA2427221C (fr) 2008-09-16
NO321952B1 (no) 2006-07-24
HRP20000182A2 (en) 2001-04-30
EA005892B1 (ru) 2005-06-30
US6476040B1 (en) 2002-11-05
YU13200A (sh) 2002-10-18
RS49836B (sr) 2008-08-07
UA70928C2 (uk) 2004-11-15
PA8491901A1 (es) 2001-12-14
CO5160273A1 (es) 2002-05-30
MY136270A (en) 2008-09-30
BG65194B1 (bg) 2007-06-29
BG104278A (en) 2001-08-31
CR6165A (es) 2008-10-10
ATE348098T1 (de) 2007-01-15
CZ299426B6 (cs) 2008-07-23
SG115536A1 (en) 2005-10-28
EA200000274A2 (ru) 2000-10-30
DE60032275D1 (de) 2007-01-25
EA200201245A1 (ru) 2003-04-24
CA2302965C (fr) 2004-02-17
NO20054715L (no) 2000-10-02
BRPI0001486B8 (pt) 2021-05-25
ES2278578T3 (es) 2007-08-16
EA005561B1 (ru) 2005-04-28
IS5411A (is) 2000-10-02
ID25427A (id) 2000-10-05
EG22506A (en) 2003-03-31
EP1044969A2 (fr) 2000-10-18
JP4074509B2 (ja) 2008-04-09
IL135245A0 (en) 2001-05-20
HUP0001353A3 (en) 2002-01-28
CN100351242C (zh) 2007-11-28
EP1044969A3 (fr) 2000-11-29
HK1029790A1 (en) 2001-04-12
JP3420549B2 (ja) 2003-06-23
CN1276370A (zh) 2000-12-13
AU2005201494B2 (en) 2008-02-07
UA80955C2 (en) 2007-11-26
AU2005201494A1 (en) 2005-05-05
CA2427221A1 (fr) 2000-09-30
NZ503683A (en) 2001-09-28
OA11335A (en) 2003-12-10
KR100430209B1 (ko) 2004-05-03
NO20001648D0 (no) 2000-03-30
KR100430210B1 (ko) 2004-05-03
PE20001599A1 (es) 2001-01-18
EA200201244A1 (ru) 2003-04-24
PL339330A1 (en) 2000-10-09
SK287339B6 (sk) 2010-07-07
SK4442000A3 (en) 2000-10-09
EE04589B1 (et) 2006-02-15
AP1265A (en) 2004-03-26
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
HUP0001353A2 (hu) 2001-05-28
DK1044969T3 (da) 2007-04-23
HU227698B1 (en) 2011-12-28
CA2302965A1 (fr) 2000-09-30
BRPI0001486B1 (pt) 2019-01-29
KR20010014658A (ko) 2001-02-26
PT1044969E (pt) 2007-05-31
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
EA004654B1 (ru) 2004-06-24
UY26086A1 (es) 2000-10-31
TW553939B (en) 2003-09-21
JP2000290262A (ja) 2000-10-17
SG121687A1 (en) 2006-05-26
AR018705A1 (es) 2001-11-28
HU0001353D0 (en) 2000-06-28
EE200000255A (et) 2000-12-15

Similar Documents

Publication Publication Date Title
TNSN00064A1 (fr) Procedes et produits intermediaires pour la preparation de composes anti-cancereux
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01082A1 (fr) Derives de thiophene nouveaux, procede pour leur preparation et compositions les contenant
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
MA24729A1 (fr) Macrolides nouveaux.
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
MA31373B1 (fr) Composes amino-heterocycliques
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
FR2708605A1 (fr) Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
MA27775A1 (fr) Composes organiques
FR2708606A1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2708608A1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
ES2379948T3 (es) Composición medicinal que comprende Tacrine o Donepezil para mejorar la función cerebral
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.